1997
Late sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1996
Oncology
DeVita V, Deisseroth A. Oncology. JAMA 1996, 275: 1833-1834. PMID: 8642736, DOI: 10.1001/jama.1996.03530470061036.Peer-Reviewed Original Research
1995
The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.
Deisseroth A, DeVita V. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. The Cancer Journal 1995, 1: 15-21. PMID: 9166447.Peer-Reviewed Original ResearchConceptsMolecular determinants of resistanceNormal tissuesSensitivity to cytotoxic agentsConventional dose therapyTherapy-induced side effectsIntroduction of chemotherapyCurative therapeutic interventionParadigm of treatmentPresence of mutationsCells to treatmentDose therapyBiologic therapySolid tumorsDeterminants of resistanceHematopoietic neoplasmsChemotherapeutic agentsChemotherapyCytotoxic agentsNeoplastic cellsSide effectsTherapyApplication of molecular analysisTherapeutic interventionsCell deathNeoplasms
1988
The role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapyCytogenetic Studies in Patients With Secondary Leukemia/Dysmyelopoietic Syndrome After Different Treatment Modalities
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic Studies in Patients With Secondary Leukemia/Dysmyelopoietic Syndrome After Different Treatment Modalities. Blood 1988, 71: 403-414. DOI: 10.1182/blood.v71.2.403.403.Peer-Reviewed Original ResearchCytogenetic studiesChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7De novo leukemiaAbstract Cytogenetic studiesCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapyCytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988, 71: 403-14. PMID: 3337904, DOI: 10.1182/blood.v71.2.403.bloodjournal712403.Peer-Reviewed Original ResearchConceptsChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7Cytogenetic studiesDe novo leukemiaCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapyOn the value of response criteria in therapeutic research.
Devita V. On the value of response criteria in therapeutic research. Bulletin Du Cancer 1988, 75: 863-9. PMID: 3061500.Peer-Reviewed Original ResearchConceptsLocal tumor presentationPrimary chemotherapyTumor presentationBiological marker of responseResponse to primary chemotherapySmall-cell lung cancerDiffuse large-cell lymphomaResponse criteriaLarge-cell lymphomaComplete remission rateRelapse-free survivalFull dose chemotherapyPrimary tumor massMarkers of responseCytoreductive effectInduction chemotherapyDose chemotherapyRemission ratePediatric malignanciesTumor massPrimary treatmentChemotherapyLung cancerInduction cyclesAlternative therapies
1987
The evolution of chemotherapy of lymphomas of adults.
DeVita V. The evolution of chemotherapy of lymphomas of adults. Leukemia 1987, 1: 467-85. PMID: 3312842.Peer-Reviewed Original ResearchDecreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease
Blayney D, Longo D, Young R, Greene M, Hubbard S, Postal M, Duffey P, DeVita V. Decreasing Risk of Leukemia with Prolonged Follow-up after Chemotherapy and Radiotherapy for Hodgkin's Disease. New England Journal Of Medicine 1987, 316: 710-714. PMID: 3821809, DOI: 10.1056/nejm198703193161203.Peer-Reviewed Original ResearchConceptsRisk of leukemiaHodgkin's diseaseAcute leukemiaNormal marrow morphologyBone marrow aspirationAcute nonlymphocytic leukemiaSecond neoplasmsMarrow aspirationNonlymphocytic leukemiaMarrow morphologyActuarial analysisPatientsBone marrowFirst treatmentPeak onsetLeukemiaMorphologic changesChemotherapyRadiation treatmentDiseaseComplicationsTreatmentRiskYearsPrevious studies
1985
Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy.
Geffen D, Fisher R, Longo D, Young R, DeVita V. Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. Journal Of Clinical Oncology 1985, 3: 646-53. PMID: 3998781, DOI: 10.1200/jco.1985.3.5.646.Peer-Reviewed Original ResearchConceptsNormal renal functionSerum creatinine levelsRenal involvementDiffuse aggressive lymphomasRenal functionCombination chemotherapyCreatinine levelsAggressive lymphomaElevated serum creatinine levelInitial local controlRecurrent renal diseaseEvidence of diseaseSite of recurrenceResults of treatmentComplete remissionDisseminated diseaseRenal diseaseSystemic diseaseHodgkin's lymphomaComplete resolutionRadiographic criteriaPatientsLocal controlLymphomaChemotherapyProMACE-MOPP combination chemotherapy for diffuse lymphomas.
Fisher R, Young R, Longo D, DeVita V. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Seminars In Oncology 1985, 12: 29-32. PMID: 2579441.Peer-Reviewed Original ResearchConceptsComplete remissionCombination chemotherapyAdvanced stageComplete response rateLong-term survivalMOPP combination chemotherapyC-MOPPComplete respondersNew regimenHodgkin's lymphomaBurkitt's lymphomaDiffuse lymphomaResponse rateFatal diseaseLymphomaPatientsDeath rateNCI studyHigh gradeRemissionChemotherapyDiseaseLarge cellsMyelosuppressionRegimen
1984
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier R, Anderson J, Costello W, Rosner G, Horton J, Glick J, Hines J, Berard C, DeVita V. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals Of Internal Medicine 1984, 101: 447-56. PMID: 6089632, DOI: 10.7326/0003-4819-101-4-447.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBlood Cell CountCarmustineClinical Trials as TopicCombined Modality TherapyCyclophosphamideFemaleGastrointestinal DiseasesHematologic DiseasesHodgkin DiseaseHumansMaleMechlorethamineNeoplasm StagingPeripheral Nervous System DiseasesPrednisoneProcarbazineRandom AllocationVinblastineVincristineConceptsAdvanced Hodgkin's diseaseHodgkin's diseaseUntreated patientsEastern Cooperative Oncology Group studyDuration of complete remissionRandomized prospective studyTreatment of patientsMOPP regimenHematologic toxicityInduction chemotherapyComplete remissionChemotherapy regimensRemission rateNeurological toxicityProspective studyMOPPRemissionTherapeutic benefitChemotherapyPatientsInduction phaseDiseaseToxicityGroup studyDuration25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE
DeVita V, Goidin A. 25 THERAPEUTIC RESEARCH IN THE NATIONAL CANCER INSTITUTE. 1984, 499-526. DOI: 10.1016/b978-0-12-667980-9.50032-4.Peer-Reviewed Original ResearchCombination of drugsTypes of tumorsNational Cancer InstituteGroup of diseasesDosage scheduleCancer therapistClinical oncologistsCancer InstituteExperimental animalsBeneficial effectsTherapeutic researchTumorsDrugsTreatmentSignificant numberField of medicineRemissionChemotherapyPatientsSurgeryOncologistsRadiotherapyCancerDiseasePhysicians
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphomaAdvances in cancer therapeutics: chemotherapy.
DeVita V. Advances in cancer therapeutics: chemotherapy. Progress In Clinical And Biological Research 1983, 132A: 47-69. PMID: 6634746.Peer-Reviewed Original ResearchConceptsTumor massEffectiveness of combination chemotherapyResistance to anti-cancer drugsCancer chemotherapyInvariable inverse relationshipPathways of drug resistanceOutcome of cancer chemotherapyOutcome of surgeryResistance to chemotherapyCell numberHistory of cancerNatural history of cancerOrigin of human cancerCombination chemotherapyAnti-cancer drugsLocal treatmentChemotherapyDrug resistanceHuman malignanciesRadiotherapyCancer therapeuticsNatural historyHuman cancersSurgeryCancer
1982
Immunological and physiological responses to whole-body hyperthermia.
Bull J, Lees D, Schuette W, Smith R, Glatstein E, DeVita V. Immunological and physiological responses to whole-body hyperthermia. National Cancer Institute Monograph 1982, 61: 177-81. PMID: 7177176.Peer-Reviewed Original Research
1981
Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease
Schilsky R, Sherins R, Hubbard S, Wesley M, Young R, DeVita V. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. The American Journal Of Medicine 1981, 71: 552-556. PMID: 7282743, DOI: 10.1016/0002-9343(81)90205-9.Peer-Reviewed Original ResearchConceptsOvarian failureMOPP chemotherapyOvarian functionChemotherapy-induced ovarian failureAge 25Causes of amenorrheaCompletion of chemotherapyPercent of patientsLong-term followTime of evaluationTime of treatmentPersistent amenorrheaChemotherapy regimenOlder patientsMedian ageHodgkin's diseaseEstradiol levelsSerum gonadotropinPatientsAmenorrheaChemotherapyNormal childrenWomenDiseaseTreatmentMultimodal treatment of primary breast carcinoma Analysis of accomplishments and problem areas
Weiss R, Henney J, DeVita V. Multimodal treatment of primary breast carcinoma Analysis of accomplishments and problem areas. The American Journal Of Medicine 1981, 70: 844-851. PMID: 7011024, DOI: 10.1016/0002-9343(81)90541-6.Peer-Reviewed Original ResearchConceptsAxillary nodesInvolved axillary nodesDisease-free survivalUse of chemotherapyBreast carcinoma patientsCertain patient groupsFuture clinical trialsPrimary breast carcinomaBetter therapeutic indexMurine tumor modelsCarcinoma patientsDrug regimensMultimodal treatmentPatient groupClinical trialsBreast carcinomaBreast cancerTherapeutic indexChemotherapy modePatientsSpecific subgroupsTumor modelMastectomyChemotherapyHuman subjectsResolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma
Broder S, Callihan T, Jaffe E, DeVita V, Strober W, Bartter F, Waldmann T. Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. Gastroenterology 1981, 80: 166-168. PMID: 7450403, DOI: 10.1016/0016-5085(81)90208-0.Peer-Reviewed Original ResearchConceptsIntestinal lymphangiectasiaCombination chemotherapyMalignant lymphomaUndifferentiated malignant lymphomaSystemic combination chemotherapyGastrointestinal protein lossProtein lossB-cell originSerum protein concentrationMonoclonal B-cell originGastrointestinal symptomsRecurrent vomitingMassive edemaIntestinal lymphangiectasisIntestinal lymphaticsGastrointestinal tractNeoplastic cellsPatientsLymphomaLymphangiectasiaInitial evaluationYr durationChemotherapyEdemaDiseaseErythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy.
Whang-Peng J, Lees D, Schuette W, Smith R, Bull J, DeVita V. Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy. Journal Of The National Cancer Institute 1981, 65: 1103-4. PMID: 7296555.Peer-Reviewed Original Research